MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP
NCT06361108
Recruiting
This Phase I, randomized, double-blind and placebo controlled study is to evaluate the safety, tolerability, and PK, and to preliminarily assess the efficacy of topically administered YJ001 in a multiple-ascending dose (MAD) fashion in the patients with DPNP. The study will be conducted at a single study center. In this study, 2 cohorts (N=24, 12 subjects for each cohort), each cohort will consist of 10 active and 2 placebo, with approximately equal numbers of male and female subjects. Each su... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/11/2025
Locations: Clinical Trials of Texas,LLC, Fredericksburg, Texas
Conditions: Diabetic Peripheral Neuropathic Pain
Register for Updates
Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
NCT05959291
Recruiting
The purpose of this preliminary research study is to see if patients discontinuing maintenance Herceptin and/or other anti-HER-2 treatments with monitoring in addition to radiologic imaging and routine blood work will stay in complete radiological remission and to determine how long patients are able to stay in complete radiological remission without treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: University of Miami, Miami, Florida
Conditions: HER2-positive Metastatic Breast Cancer, Stage IV Breast Cancer
Register for Updates
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
NCT06103864
Recruiting
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Research Site, Daphne, Alabama +307 locations
Conditions: Breast Cancer
Register for Updates
Platelet Rich Plasma Injections In Young And Old Human Subjects
NCT06451120
Recruiting
This is a randomized, double-blind, placebo-controlled phase 2 study with a secondary crossover phase at the end of the initial trial to ensure all subjects receive one PRP injection. The goal is to identify what proteins change in the blood following repeated intraarticular knee PRP injections in patients with knee osteoarthritis. The objective is to determine the protein changes resulting from a single autologous PRP injection (5 mL) in comparison to a normal saline control. About 60 subjects... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/11/2025
Locations: University of California, San Francisco, California
Conditions: Osteoarthritis, Articular Cartilage, Musculoskeletal Disorders
Register for Updates
Music Listening for Mental Health Recovery After Stroke
NCT07127159
Recruiting
This study aims to explore whether listening to music intentionally can support the mental health of people recovering from a stroke. The question the investigators aim to answer is: Can intentional music listening improve emotional well-being in stroke survivors? And if so, what kinds of changes might music listening induce in mental health, thinking and memory (cognition), and brain activity? Participants will be randomly assigned to listen to either music or an audiobook for one hour each da... Read More
Gender:
ALL
Ages:
Between 50 years and 90 years
Trial Updated:
08/11/2025
Locations: New York University, New York, New York
Conditions: Stroke
Register for Updates
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
NCT06456593
Recruiting
This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase. The objective is to evaluate the efficacy and safety of obefazimod compared to placebo as induction and maintenance therapy in subjects with moderately to severely active CD after inadequate response (no response, loss of response, or intolerance) to conventional therapies and/or advanced therapies. The primary objective for the 48-Week Extension Phase is to evaluate the sa... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/11/2025
Locations: IMC Gulf Coast Gastroenterology, PC, Fairhope, Alabama +148 locations
Conditions: Moderately to Severely Active Crohn Disease
Register for Updates
Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)
NCT06434350
Recruiting
To learn if the combination of enfortumab vedotin plus radiation therapy could help to control the disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Bladder Cancer
Register for Updates
Effect of Transcutaneous Electrical Nerve Stimulation on Post-stroke Patients
NCT06541015
Recruiting
The subjects will be asked to attend minimum 15 separate sessions, 6 for testing changes in reflex behaviors, 3 for testing changes in the influence of descending motor tracts on spinal motor neurons, 3 for each testing functional movement in response to a trip event and cross-tilt walking adaptation pattern, as part of their participation in the research study. The estimated amount of time to enroll and collect the data for each of the subjects is four months' time. The data will be analyzed an... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/11/2025
Locations: University of Texas Medical Center, Dallas, Texas
Conditions: Hemiplegia and/or Hemiparesis Following Stroke, Anterior Circulation Stroke of Uncertain Pathology
Register for Updates
Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.
NCT06450925
Recruiting
The investigators hypothesize that single oral high dose supplementation with vitamin A will reduce the incidence of moderate-severe chronic graft-versus-host disease (GVHD) compared with placebo.
Gender:
ALL
Ages:
All
Trial Updated:
08/11/2025
Locations: Moffitt Cancer Center, Tampa, Florida +2 locations
Conditions: Graft Vs Host Disease, Vitamin A Deficiency, Vitamin D Deficiency
Register for Updates
GLP-1R Agonist Treatment for Opioid Use Disorder
NCT06548490
Recruiting
The goal of this clinical trial is to learn if semaglutide can reduce illicit opioid use in adults in outpatient treatment for opioid use disorder, and who are receiving either buprenorphine or methadone maintenance treatment. The main question it aims to answer is: • Does semaglutide increase the likelihood that participants will refrain from using illicit and nonprescribed opioids? The investigators will compare semaglutide to a placebo (a needle prick that contains no drug) to see if semagl... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/11/2025
Locations: University of Maryland Baltimore, Baltimore, Maryland +2 locations
Conditions: Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders, Chemically-Induced Disorders, Mental Disorder, Opioid
Register for Updates
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period.
NCT06524375
Recruiting
The main purpose of the study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease \[uMRD \< or 10\^-4 in peripheral blood (PB)\] by end of combination treatment (EOCT) to allow off-treatment period. The acronym BRAVE stands for Btki Responders to Achieve deep remission (or off-treatment periods) with VEnetoclax.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Highlands Oncology Group, Springdale, Arkansas +20 locations
Conditions: Chronic Lymphocytic Leukemia
Register for Updates
The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality
NCT07127354
Recruiting
The goal of this clinical trial is to learn how GLP-1 and GIP agonists effect bowel preparation in patients scheduled for colonoscopies. The main questions it aims to answer are: * Does GLP-1 and GIP agonist increase the rate of inadequate bowel preparation? * Does the quality of bowel preparation differ in patients who hold vs. those who continue a single dose of their GLP-1 or GIP agonist medication? * Are there any differences in the rates of complications gastric aspiration in patients who... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Cleveland Clinic, Cleveland, Florida +1 locations
Conditions: GLP - 1, Bowel Preparation for Colonoscopy
Register for Updates